J
Justine E. Roderick
Researcher at University of Massachusetts Medical School
Publications - 31
Citations - 2693
Justine E. Roderick is an academic researcher from University of Massachusetts Medical School. The author has contributed to research in topics: Notch signaling pathway & Small hairpin RNA. The author has an hindex of 18, co-authored 30 publications receiving 2158 citations. Previous affiliations of Justine E. Roderick include University of Massachusetts Amherst.
Papers
More filters
Journal ArticleDOI
RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer
Andrew Wolfe,Kamini Singh,Yi Zhong,Philipp Drewe,Vinagolu K. Rajasekhar,Viraj Sanghvi,Konstantinos J. Mavrakis,Man Jiang,Justine E. Roderick,Joni Van der Meulen,Jonathan H. Schatz,Christina M. Rodrigo,Chunying Zhao,Pieter Rondou,Elisa de Stanchina,Julie Teruya-Feldstein,Michelle A. Kelliher,Franki Speleman,John A. Porco,Jerry Pelletier,Gunnar Rätsch,Hans-Guido Wendel +21 more
TL;DR: An eIF4A RNA helicase-dependent mechanism of translational control that contributes to oncogenesis and underlies the anticancer effects of silvestrol and related compounds is reported.
Journal ArticleDOI
An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia.
Birgit Knoechel,Justine E. Roderick,Kaylyn E. Williamson,Jiang Zhu,Jens G. Lohr,Matthew J. Cotton,Shawn M. Gillespie,Daniel Fernandez,Manching Ku,Hongfang Wang,Federica Piccioni,Serena J. Silver,Mohit Jain,Daniel S. Pearson,Michael J. Kluk,Christopher J. Ott,Leonard D. Shultz,Michael A. Brehm,Dale L. Greiner,Alejandro Gutierrez,Kimberly Stegmaier,Andrew L. Kung,David E. Root,James E. Bradner,Jon C. Aster,Michelle A. Kelliher,Bradley E. Bernstein +26 more
TL;DR: A role for epigenetic heterogeneity in leukemia resistance is established that may be addressed by incorporating epigenetic modulators in combination therapy, and the GSI-JQ1 combination was found to be effective against primary human leukemias in vivo.
Journal ArticleDOI
BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment.
Georg E. Winter,Georg E. Winter,Andreas Mayer,Dennis L. Buckley,Michael A. Erb,Justine E. Roderick,Sarah Vittori,Jaime M. Reyes,Julia di Iulio,Amanda Souza,Christopher J. Ott,Justin M. Roberts,Rhamy Zeid,Thomas G. Scott,Joshiawa Paulk,Kate C. Lachance,Calla M. Olson,Shiva Dastjerdi,Sophie Bauer,Charles Y. Lin,Nathanael S. Gray,Michelle A. Kelliher,L. Stirling Churchman,James E. Bradner,James E. Bradner +24 more
TL;DR: These studies establish a mechanism-based rationale for the development of BET bromodomain degradation as cancer therapy and show that BET degradation prompts a collapse of global elongation that phenocopies CDK9 inhibition.
Journal ArticleDOI
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
Elizabeth C. Townsend,Mark A. Murakami,Alexandra N. Christodoulou,Amanda L. Christie,Johannes Köster,Tiffany DeSouza,Elizabeth A. Morgan,Scott P. Kallgren,Huiyun Liu,Shuo-Chieh Wu,Olivia Plana,Joan Montero,Kristen E. Stevenson,Prakash Rao,Raga Vadhi,Michael Andreeff,Philippe Armand,Karen K. Ballen,Patrizia Barzaghi-Rinaudo,Sarah Cahill,Rachael A. Clark,Vesselina G. Cooke,Matthew S. Davids,Daniel J. DeAngelo,David M. Dorfman,Hilary Eaton,Benjamin L. Ebert,Julia Etchin,Brant Firestone,David C. Fisher,Arnold S. Freedman,Ilene Galinsky,Hui Gao,Jacqueline S. Garcia,Francine Garnache-Ottou,Timothy A. Graubert,Alejandro Gutierrez,Alejandro Gutierrez,Ensar Halilovic,Marian H. Harris,Zachary T. Herbert,Steven M. Horwitz,Giorgio Inghirami,Andrew M. Intlekofer,Moriko Ito,Shai Izraeli,Eric D. Jacobsen,Caron A. Jacobson,Sébastien Jeay,Irmela Jeremias,Michelle A. Kelliher,Raphael Koch,Marina Konopleva,Nadja Kopp,Steven M. Kornblau,Andrew L. Kung,Thomas S. Kupper,Nicole R. LeBoeuf,Ann S. LaCasce,Emma Lees,Loretta S. Li,A. Thomas Look,Masato Murakami,Markus Müschen,Donna Neuberg,Samuel Y. Ng,Oreofe O. Odejide,Stuart H. Orkin,Rachel R. Paquette,Andrew E. Place,Justine E. Roderick,Jeremy Ryan,Stephen E. Sallan,Brent Shoji,Lewis B. Silverman,Robert J. Soiffer,David P. Steensma,Kimberly Stegmaier,Richard Stone,Jerome Tamburini,Aaron R. Thorner,Paul Van Hummelen,Martha Wadleigh,Marion Wiesmann,Andrew P. Weng,Jens Wuerthner,David A. Williams,Bruce M. Wollison,Andrew A. Lane,Anthony Letai,Monica M. Bertagnolli,Jerome Ritz,Myles Brown,Henry W. Long,Jon C. Aster,Margaret A. Shipp,James D. Griffin,David M. Weinstock,David M. Weinstock +98 more
TL;DR: It is demonstrated that large studies of acute leukemia PDXs that mimic human randomized clinical trials can characterize drug efficacy and generate transcriptional, functional, and proteomic biomarkers in both treatment-naive and relapsed/refractory disease.
Journal ArticleDOI
Cutting Edge: RIPK1 Kinase Inactive Mice Are Viable and Protected from TNF-Induced Necroptosis In Vivo
Apostolos Polykratis,Nicole Hermance,Matija Zelic,Justine E. Roderick,Chun Kim,Trieu-My Van,Thomas H. Lee,Francis Ka-Ming Chan,Manolis Pasparakis,Michelle A. Kelliher +9 more
TL;DR: Genetic evidence is provided that the kinase activity of RIPK1 is not required for survival but is essential for TNF-, TRIF-, and viral-initiated necroptosis.